美股三大指数小幅高开 脑再生科技跌超29% 智通财经6月18日电，美股三大指数小幅高开，纳指涨0.04%，道指涨0.01%，标普500指数涨0.08%。脑 再生科技跌超29%，此前2个交易日累涨近400%。 ...

今天上午，陆家嘴论坛2天议程里，最重要的部分结束了，各大监管机构的负责人分别进行了发言，有些人会觉得略失望，因为没有听到自己想 听到的信息——那些 巨大的数字，性感的举措，积极的展望 。 不过，理性来看，这其实也可以理解，5月7日，刚刚召开了"一揽子金融政策"发布会，大家可以回顾下《 为什么我对今天的发布会很乐观 》， 卖方洋洋洒洒整理出来的具体政策，就有接近30条，而短短40天之后，要再憋出30条新的重磅来，这既不现实，也无必要。 实际上，这次陆家嘴论坛召开的背景和主题，听下来很明确，就两个。 一是加大对外开放，这主要是说给外资们听的，背景就是在贸易摩擦加剧、美元信用走弱的宏观背景下，怎么样，把朋友搞得多多的。 二是加大对上海金融中心的支持。 所以， 我个人依然对论坛传递的信息和信号，"很乐观" ，即使没有比较浅白的，那些巨大的数字、性感的举措、积极的展望，有几个点，也值得展开简 单聊聊。 一共9条。 ...... 1、股民最关心的，当然还是科创成长层的设立。 很多人一看到这条信息，就条件反射般地开始阴阳——又要加速圈钱了。 其实，我们在《 腾讯回A股上市？ 》里，明确说过观点： 不应该把IPO当做洪水猛兽 ...

Core Viewpoint - The new round of reforms for the Sci-Tech Innovation Board (STAR Market) aims to enhance the inclusiveness and adaptability of the system, focusing on deepening reforms to better support comprehensive innovation in the capital market ecosystem [1] Group 1: Reform Measures - The first reform measure involves introducing a system for seasoned professional institutional investors for companies applying under the fifth set of listing standards [1][2] - This reform is inspired by practices in overseas markets, where seasoned professional institutional investors' participation is considered a reference factor in the review and registration process for companies [2] Group 2: Market Practices and Success Stories - Successful experiences from mature overseas markets show that private equity (PE) and venture capital (VC) have played crucial roles in the commercialization of advanced technologies [3] - For instance, companies listed under the Hong Kong Stock Exchange's specific rules for biotech and specialized technology firms have seen significant growth in revenue and reduction in losses after attracting seasoned investors [3] Group 3: Challenges in Identifying Quality Enterprises - Identifying and assessing the technological attributes and commercial prospects of innovative enterprises remains a challenge, particularly for unprofitable companies with high R&D costs and long commercialization cycles [4] - The market mechanism, particularly through seasoned professional institutional investors, offers unique advantages in accurately identifying quality technology firms [5] Group 4: Investment Ecosystem and Future Steps - The investment ecosystem has evolved with diverse participants, including government investment funds and private equity firms, providing substantial funding support to technology companies at various stages [6] - Approximately 90% of companies listed on the STAR Market received private equity investment prior to their listing, indicating a solid foundation for the pilot program of the seasoned professional institutional investor system [6]

Group 1 - June is typically a month of consolidation across various asset classes, including currencies, commodities, and stocks [1] - Historically, the S&P 500 index shows a slight increase of 0.2% in June since 1950 [2] - The first week of June tends to perform strongly, stabilizing in the middle of the month, and then declining towards the end [4] Group 2 - June has been identified as a month with significant factor rotation, with quality, momentum, and size factors performing well, while value factors lag [8] - If seasonal patterns hold, June is expected to favor high-quality large-cap growth stocks, which are positioned at the intersection of all factor tilts [10] Group 3 - The European quality factor may rebound in June, as seasonal factors support long/short quality factor strategies [11] - The healthcare sector has historically performed well in June, with an average increase of 0.8% relative to the S&P 500 index [13] Group 4 - The biotechnology sector is particularly strong seasonally, suggesting that going long on the biotechnology index (XBI) may be the best strategy for the healthcare sector in June [15] - Historically, gold performs poorly in June but marks the end of a seasonal downturn, with significant improvement expected in July [15][17]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 股份購回進程及業務更新 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東（「股東」）及潛在投資者有關本集團於市場上進行 股份購回的進程及業務的最近更新。 茲提述本公司日期為2025年1月2日及2025年4月10日的公告，內容有關於市場上 購回總額達2.4億港元的股份的計劃，考慮到現時交易價格水平低估了本公司內 在價值、業務前景或近期業務成果。於2025年6月17日，本公司於公開市場購回 股份，涉資近9百萬港元，在2025年對於在香港聯合交易所有限公司上市的生物 科技公司而言，屬重大購回金額。回購進度的加速體現了本公司致力提升股東價 值並對本公司長遠增長前景充滿信心。本公司可根據市場情況授權進一步購回計 劃，惟須遵守 ...

Group 1 - The first "doubling fund" in the public fund market for 2025 is the Huatai-PineBridge Hong Kong Advantage Selection A, which has achieved a 99.5% year-to-date return as of June 13, 2025, leading the entire market [1][2] - Among the top 10 funds for year-to-date returns in 2025, 8 are heavily invested in pharmaceutical companies, particularly in the innovative drug sector [1][2] - The innovative drug sector has seen significant growth, with the Wind Innovative Drug Concept Index rising over 25% and the Hang Seng Innovative Drug Index increasing over 53% since April 9, 2025 [2][3] Group 2 - Notable stocks in the innovative drug sector have experienced substantial price increases, with Shuyou Pharmaceutical leading at a 478.84% increase, followed by Sanofi Health at 129.81% [3][4] - The top-performing funds have a high concentration of investments in innovative drug companies, with the most frequently held stock being Kelong Biotechnology-B, which has also doubled in price [4][5] - Fund managers of the top-performing funds are predominantly new faces, with half of them having less than two years of investment experience [5][6] Group 3 - Zhang Wei, the manager of Huatai-PineBridge Hong Kong Advantage Selection A, has maintained a strong focus on the pharmaceutical sector, with the fund's top holdings consistently being in the biopharmaceutical industry [7][8] - The fund has shown resilience despite previous years of losses, with a significant recovery in 2025 attributed to the performance of its long-held innovative drug stocks [9][10] - Zhang Wei's investment strategy emphasizes long-term perspectives and stability in holdings, focusing on companies with global competitiveness and growth potential in the pharmaceutical and biotech sectors [10][11] Group 4 - The performance disparity among active equity funds in 2025 is notable, with 12 funds experiencing declines of over 20%, including several managed by Jin Zicai [13][14] - Jin Zicai's aggressive investment style has led to high turnover rates and concentrated positions, which can result in significant volatility [15][16] - The overall market sentiment towards innovative drugs remains positive, with expectations for continued growth driven by domestic medical demand recovery and supportive policies [10][11]

Core Viewpoint - The article discusses the extreme measures taken by Bryan Johnson, a Silicon Valley entrepreneur, in his pursuit of anti-aging and longevity, including blood transfusions and a rigorous supplement regimen, while questioning the societal implications of such pursuits [2][4][22]. Group 1: Bryan Johnson's Anti-Aging Methods - Bryan Johnson consumes 111 supplements daily and has invested in various advanced therapies, including gene therapy and blood plasma therapy, to slow down his aging process [9][22]. - He has developed a personalized life algorithm by monitoring over 70 organs, aiming to optimize his health and longevity [9][20]. - Johnson's aging coefficient is reported to be 0.54, indicating he has effectively slowed his biological aging compared to the average [18][20]. Group 2: Societal and Ethical Implications - The article raises questions about the ethical boundaries of Johnson's methods, particularly his blood transfusion practices with his son, which have sparked public debate [22][24]. - Johnson compares the risks of his therapies to the dangers of fast food consumption, suggesting that societal norms around health and risk are misaligned [24][25]. - The pursuit of anti-aging is framed as a broader trend among wealthy Silicon Valley figures, highlighting a cultural obsession with overcoming mortality [6][8]. Group 3: General Health Recommendations - Despite his extreme measures, Johnson emphasizes basic health principles such as proper diet, sleep, and exercise, suggesting that these are foundational to longevity [15][30]. - He proposes a structured daily routine to optimize health, including specific meal timing to improve sleep quality and overall well-being [29][30].

General Principles - The external guarantee management system of Beijing Hotgen Biotech Co., Ltd. aims to standardize external guarantee behavior, effectively control risks, and ensure asset safety for the company's stable development [1][2] - The system is established based on various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2] Basic Requirements - External guarantees must adhere to principles of legality, prudence, mutual benefit, and safety, with strict risk control [3] - Any external guarantee provided by the company must be approved by the board of directors or shareholders [3][6] Approval Procedures - The company can provide external guarantees to entities with independent legal status and sufficient repayment ability, including subsidiaries under actual control [4][5] - The approval process involves a thorough review of the financial status and creditworthiness of the guaranteed party [5][6] Contract Signing - All external guarantees must be formalized in written contracts that comply with relevant laws and regulations [8][9] - The contracts should clearly define the rights and obligations of both parties, including the type and amount of the principal debt [8][9] Management of Guarantees - The company’s board of directors, shareholders, and finance department are responsible for decision-making and management of guarantee activities [9][10] - Continuous monitoring of the guaranteed party's financial health and compliance with the guarantee contract is required [10][11] Responsibilities - The company must strictly follow the established system for providing guarantees, with accountability for any violations leading to losses [12][13] - Individuals who exceed their authority in signing guarantee contracts without proper approval may face legal consequences [12][13]

北京热景生物技术股份有限公司董事会提名委员会 经审阅公司第四届董事会独立董事候选人宋云锋先生、徐小舸女士、李梦涓 女士的个人履历等相关资料,上述独立董事候选人未持有公司股份,与公司控股 股东、实际控制人、持有公司 5%以上股份的股东及其他董事、监事、高级管理 人员之间不存在关联关系,不存在《公司法》及《公司章程》规定的不得担任独 立董事的情形;不存在被中国证监会确定为市场禁入者且尚在禁入期的情形,也 不存在被证券交易所公开认定不适合担任上市公司独立董事的情形,不属于失信 被执行人,符合《公司法》《上海证券交易所科创板股票上市规则》《上市公司独 立董事管理办法》等相关法律法规、规范性文件及《公司章程》规定的任职资格 和独立性要求。 上述独立董事候选人具有丰富的专业知识,熟悉相关法律、行政法规、规章 与规则,其任职资格、教育背景、工作经历、业务能力符合公司独立董事任职要 求。 综上,我们同意提名宋云锋先生、徐小舸女士、李梦涓女士为公司第四届董 事会独立董事候选人,并同意将该事项提交公司董事会审议。 北京热景生物技术股份有限公司董事会提名委员会 关于第四届董事会独立董事候选人任职资格的审查意见 根据《中华人民共和国 ...

6月17日港股市场，北水成交净买入63.02亿港元，其中港股通(沪)成交净买入35.8亿港元，港股通(深)成 交净买入27.22亿港元。 北水净买入最多的个股是建设银行（601939）(00939)、阿里巴巴-W(09988)、泡泡玛特(09992)。北水净 卖出最多的个股是腾讯(00700)、石药集团(01093)、中海油(00883)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 山东墨龙 HK 00568 | 19.60 乙 | 19.70亿 | 39.30亿 -975.30万 | | 泡泡玛特 | 19.90 亿 | 17.65 乙 | 37.56亿 | | HK 09992 | | | +2.25 乙 | | 建设银行 | 16.66 亿 | 5.441Z | 22.10亿 | | HK 00939 | | | +11.22 乙 | | 阿里巴巴-W | 12.26 乙 | 8.72亿 | 20.97亿 | | HK 09988 | | | +3.54 乙 | | 南京熊猫 ... | 9.50亿 | 7 ...